Good evening :)
$
₹
AIM ImmunoTech Inc

AIM ImmunoTech Inc

AIM

AMEX
Asset Logo

AIM ImmunoTech Inc

AIM

AMEX
$0.222.01% (-0.00)
$
₹
$0.222.01% (-0.00)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $6.9M the stock is ranked 5831

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0.91
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.71
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0.70
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 2 analysts' reports

Buy
2 analysts
Hold
0 analyst
Sell
0 analyst

Analysts expect a +1767.31% price upside over the next year

Current Price$0.22
Target Price$4.25

Company Profile

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
72.44
72.44
1Y Return
23.04%
23.04%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.17
27.17
1Y Return
57.21%
57.21%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
34.82%
34.82%
Buy Reco %
63.33
63.33
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
31.84
31.84
1Y Return
37.58%
37.58%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
20.49
20.49
1Y Return
46.1%
46.1%
Buy Reco %
76.00
76.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
AIM ImmunoTech Inc -0.910.70
AbbVie Inc72.4450.450.37
Amgen Inc27.1720.542.13

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

0
-3.2
0
-4.1
0
-3
0
-3.7
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ2 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0.040.050.030.040.010.020.020.020.020.02
Net Income-5.81-1.83-3.7-5.96-3.70-2.79-3.28-4.17-3.02-3.78
Net Profit Margin-14542.50%-3672%-10571.42%-13260%-23156.25%-11176%-12630.76%-19880.95%-13740.90%-14569.23%
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. AIM ImmunoTech Inc (AIM) share price today is $0.22 as of September 5, 2026 at 1:30 AM IST. The stock touched a day high of $0.24 and a day low of $0.22.

  2. AIM ImmunoTech Inc stock trades on AMEX under the ticker symbol AIM.

  3. AIM ImmunoTech Inc's market capitalization is $6.92M as of September 5, 2026 at 1:30 AM IST.

  4. AIM ImmunoTech Inc's price-to-earnings (P/E) ratio is N/A as of September 7, 2026.

  5. AIM ImmunoTech Inc's price-to-book (P/B) ratio is 0.91 as of September 7, 2026.

  6. Yes, You can buy AIM ImmunoTech Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy AIM ImmunoTech Inc shares in three steps: 1. Search AIM ImmunoTech Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since AIM ImmunoTech Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in AIM ImmunoTech Inc (AIM) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 43.6681 shares at the current price of $0.22.

Loading...